The stock of Achieve Life Sciences Inc (ACHV) has gone up by 21.59% for the week, with a 45.08% rise in the past month and a 32.99% rise in the past quarter. The volatility ratio for the week is 8.61%, and the volatility levels for the past 30 days are 6.13% for ACHV. The simple moving average for the past 20 days is 24.61% for ACHV’s stock, with a 4.40% simple moving average for the past 200 days.
Is It Worth Investing in Achieve Life Sciences Inc (NASDAQ: ACHV) Right Now?
The 36-month beta value for ACHV is also noteworthy at 1.64. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ACHV is 29.37M, and at present, short sellers hold a 8.98% of that float. The average trading volume of ACHV on June 05, 2025 was 221.80K shares.
ACHV) stock’s latest price update
Achieve Life Sciences Inc (NASDAQ: ACHV)’s stock price has gone decline by -9.03 in comparison to its previous close of 4.21, however, the company has experienced a 21.59% increase in its stock price over the last five trading days. seekingalpha.com reported 2025-06-03 that Achieve Life Sciences (ACHV) is positioned for growth with its lead smoking cessation therapy, cytisinicline, advancing through late-stage clinical trials. The company addresses a significant unmet need in tobacco addiction, with cytisinicline showing promising efficacy and safety data compared to existing therapies. While FDA approval may be difficult, the low valuation and high potential peak sales provide a decent risk/reward profile.
Analysts’ Opinion of ACHV
Many brokerage firms have already submitted their reports for ACHV stocks, with Rodman & Renshaw repeating the rating for ACHV by listing it as a “Buy.” The predicted price for ACHV in the upcoming period, according to Rodman & Renshaw is $12 based on the research report published on November 14, 2024 of the previous year 2024.
Raymond James, on the other hand, stated in their research note that they expect to see ACHV reach a price target of $20. The rating they have provided for ACHV stocks is “Strong Buy” according to the report published on September 27th, 2024.
Maxim Group gave a rating of “Buy” to ACHV, setting the target price at $20 in the report published on May 10th of the previous year.
ACHV Trading at 43.17% from the 50-Day Moving Average
After a stumble in the market that brought ACHV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.36% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACHV starting from Oki Mark K, who purchase 10,000 shares at the price of $2.89 back on Mar 17 ’25. After this action, Oki Mark K now owns 10,000 shares of Achieve Life Sciences Inc, valued at $28,887 using the latest closing price.
Stewart Richard Alistair, the Chieve Executive Officer of Achieve Life Sciences Inc, purchase 10,000 shares at $2.86 during a trade that took place back on Mar 17 ’25, which means that Stewart Richard Alistair is holding 60,876 shares at $28,598 based on the most recent closing price.
Stock Fundamentals for ACHV
The total capital return value is set at -1.02. Equity return is now at value -154.55, with -94.80 for asset returns.
Based on Achieve Life Sciences Inc (ACHV), the company’s capital structure generated 0.49 points at debt to capital in total, while cash flow to debt ratio is standing at -3.57. The debt to equity ratio resting at 0.97. The interest coverage ratio of the stock is -17.47.
Currently, EBITDA for the company is -37.42 million with net debt to EBITDA at 0.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.51.
Conclusion
In summary, Achieve Life Sciences Inc (ACHV) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
